Investing
This new funding round brings the company's total raise to roughly $62.5 million.
The clinical trial results will be used to expand Viome’s mRNA platform, which in May received FDA breakthrough device designation for identifying early signs of oral and throat cancers.
The new funding round brings the company's valuation to $4.6 billion.
The company said the latest round brings its total raise to $47 million.
This IPO comes roughly a year after the company closed a $25 million SPAC.
The company will cater to individuals with serious mental illness and severe depression.
Also: Pediatric sleep app Huckleberry raises $12.5 million, and illumigyn, maker of a platform for remote gynecological imaging, brings in $33 million.
The company said its valuation is now $1.4 billion.
The latest round follows a $14 million Series B raise from 2019.
The company said the Series B brings its total raise to $20 million.